ANGLE plc (AGL) - Product Pipeline Analysis, 2021 Update

Summary

ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and foetal health products. The company develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention, treatment, and monitoring of disease. Its product Parsortix cell separation system, which captures very rare circulating tumor cells in cancer patient blood. ANGLE’s Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. Its cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The company provides liquid biopsy (blood test) that enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. Its harvested CTCs have a range of applications such as diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring. The company has operations in the US and the UK. ANGLE is headquartered in Guildford, Surrey, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company ANGLE plc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


ANGLE plc Company Overview
ANGLE plc Company Snapshot
ANGLE plc Pipeline Products and Ongoing Clinical Trials Overview
ANGLE plc – Pipeline Analysis Overview
ANGLE plc - Key Facts
ANGLE plc - Major Products and Services
ANGLE plc Pipeline Products by Development Stage
ANGLE plc Ongoing Clinical Trials by Trial Status
ANGLE plc Pipeline Products Overview
HyCEAD Ziplex System - Ovarian Cancer Assay
HyCEAD Ziplex System - Ovarian Cancer Assay Product Overview
HyCEAD Ziplex System - Ovarian Cancer Assay Clinical Trial
Parsortix GEN2
Parsortix GEN2 Product Overview
Parsortix PC1 System
Parsortix PC1 System Product Overview
Parsortix System - Renal Carcinoma
Parsortix System - Renal Carcinoma Product Overview
Parsortix Test - Brain Metastasis
Parsortix Test - Brain Metastasis Product Overview
Parsortix-Based Test - Colorectal Cancer
Parsortix-Based Test - Colorectal Cancer Product Overview
Parsortix-Based Test - Head & Neck Cancer
Parsortix-Based Test - Head & Neck Cancer Product Overview
Parsortix-Based Test - Lung Cancer
Parsortix-Based Test - Lung Cancer Product Overview
Parsortix-Based Test - Lung Cancer Clinical Trial
Parsortix-Based Test - Ovarian Cancer Triage
Parsortix-Based Test - Ovarian Cancer Triage Product Overview
Parsortix-Based Test - Ovarian Cancer Triage Clinical Trial
Parsortix-Based Test - Pancreatic Cancer
Parsortix-Based Test - Pancreatic Cancer Product Overview
Parsortix-Based Test - Prostate Cancer
Parsortix-Based Test - Prostate Cancer Product Overview
ANGLE plc - Key Competitors
ANGLE plc - Key Employees
ANGLE plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
ANGLE plc, Recent Developments
Jun 18, 2021: Angle announce Annual General Meeting update
Mar 03, 2020: Angle announce breakthrough research highlights potential for parsortix to assess risk of brain metastasis in lung cancer
Feb 25, 2020: ANGLE announce Tri-Con presentation with BioView
Feb 17, 2020: ANGLE announces leading kol publishes analytical and clinical data demonstrating key advantages of Parsortix system
Feb 11, 2020: Angle announces study demonstrates Parsortix potential in melanoma
Jan 30, 2020: ANGLE: Interim results for the six months ended 31 October 2019
Jan 22, 2020: Angle announces successful face-to-face meeting with FDA
Jan 22, 2020: Successful face-to-face meeting with FDA to review Parsortix Q-Submission
Nov 07, 2019: Leading Cancer Centre demonstrates use of Parsortix In Melanoma
Oct 04, 2019: European patent granted to Queen Mary University London for megakaryocyte analysis to assess aggressiveness of prostate cancer
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
ANGLE plc Pipeline Products and Ongoing Clinical Trials Overview
ANGLE plc Pipeline Products by Equipment Type
ANGLE plc Pipeline Products by Indication
ANGLE plc Ongoing Clinical Trials by Trial Status
ANGLE plc, Key Facts
ANGLE plc, Major Products and Services
ANGLE plc Number of Pipeline Products by Development Stage
ANGLE plc Pipeline Products Summary by Development Stage
ANGLE plc Ongoing Clinical Trials by Trial Status
ANGLE plc Ongoing Clinical Trials Summary
HyCEAD Ziplex System - Ovarian Cancer Assay - Product Status
HyCEAD Ziplex System - Ovarian Cancer Assay - Product Description
HyCEAD Ziplex System - Ovarian Cancer Assay - Study Evaluates the Use of ANGLE's Combined Parsortix and HyCEAD Ziplex Platforms as a Simple Blood Test to Detect the Presence of Ovarian Cancer
Parsortix GEN2 - Product Status
Parsortix GEN2 - Product Description
Parsortix PC1 System - Product Status
Parsortix PC1 System - Product Description
Parsortix System - Renal Carcinoma - Product Status
Parsortix System - Renal Carcinoma - Product Description
Parsortix Test - Brain Metastasis - Product Status
Parsortix Test - Brain Metastasis - Product Description
Parsortix-Based Test - Colorectal Cancer - Product Status
Parsortix-Based Test - Colorectal Cancer - Product Description
Parsortix-Based Test - Head & Neck Cancer - Product Status
Parsortix-Based Test - Head & Neck Cancer - Product Description
Parsortix-Based Test - Lung Cancer - Product Status
Parsortix-Based Test - Lung Cancer - Product Description
Parsortix-Based Test - Lung Cancer - A Longitudinal Study Evaluating Molecular Changes Associated with Resistance to First and Third (AZD9291) Generation EGFR TKIs in Patients with EGFR Mutant NSCLC Using Liquid Biopsy
Parsortix-Based Test - Lung Cancer - Evaluation of Non-small Cell Lung Carcinoma Genetic Heterogeneity in Patients with Operable Early Stage Disease and Prediction of Clinical Relapse Using a Personalized Liquid Biopsy
Parsortix-Based Test - Ovarian Cancer Triage - Product Status
Parsortix-Based Test - Ovarian Cancer Triage - Product Description
Parsortix-Based Test - Ovarian Cancer Triage - Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting with a Pelvic Mass: ANG-003 EMBER Study
Parsortix-Based Test - Ovarian Cancer Triage - Study Evaluates the Use of ANGLE's Combined Parsortix and HyCEAD Ziplex Platforms as a Simple Blood Test to Detect the Presence of Ovarian Cancer
Parsortix-Based Test - Pancreatic Cancer - Product Status
Parsortix-Based Test - Pancreatic Cancer - Product Description
Parsortix-Based Test - Prostate Cancer - Product Status
Parsortix-Based Test - Prostate Cancer - Product Description
ANGLE Plc, Key Employees
ANGLE Plc, Other Locations
Glossary
List of Figures
ANGLE plc Pipeline Products by Equipment Type
ANGLE plc Pipeline Products by Development Stage
ANGLE plc Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook